Shankar et al (2015) British Journal of Haematology
Link to abstract: http://onlinelibrary.wiley.com/doi/10.1111/bjh.12055/abstract
Retrospective data collection, with pathological review of 60 biopsies (CCLG, Euronet PHL-LP1, OK Children’s Cancer Study Group HD3) between 2001 and 2014. Aim to evaluate treatment outcome in patients with histopathological variants of nodular lymphocyte predominant HL (nLPHL) after de-escalation of therapy. Patients: 5-16 years (med: 14y.o.); 47 with typical (nLPHL), 13 with variant nLPHL. 14 were treated with excision alone; 46 treated with chemo (40 CVP, 16 other regimens).
*Compared to nLPHL, variant nLPHL is associated with lower complete response rates (CCR: 46% vs 81%) p = 0.029. There were trends seen which were not significant: Higher stage at diagnosis (stage III: 23% vs 6%) and increased risk of relapse (15% vs 4%).